Abstract
Aim:
The overexpression of the human tissue kallikrein (HK) gene can reduce blood pressure and ameliorate the secondary syndromes associated with hypertension in animal models. The current study was designed to investigate hy-potensive effect of intramuscular delivery of HK gene.
Methods:
We generated an recombinant adeno-associated virus (rAAV) vector expressing human tissue kallikrein under the control of a cytomegalovirus promoter and administered the rAAV-HK vector to a spontaneously hypertensive rat model at a dose of 1×1010 virons/rat through intramuscular injection.
Results:
A persistent, high-level expression of HK post-gene delivery was confirmed by ELISA. The systolic blood pressure in the rats receiving rAAV-LacZ and saline increased from 171.3 mmHg to 182.3 mmHg 28 weeks' post injection. In contrast, the delivery of the HK gene by AAV vectors attenuated the increase of the systolic blood pressure in the treated group. The systolic blood pressure was only slightly lowered (from a level of 174 mmHg to 170.5 mmHg) post-vector administration. The difference in blood pressure between the treated group and the control groups is statistically significant at 12.6 mmHg. The hypotensive effect of rAAV-HK persisted until the end of the testing period. In addition, a significant amelioration of cardiovascular hypertrophy, renal injury, and collagen depositions in the rAAV-HK-treated animals were also observed.
Conclusion:
All the effects are comparable with those of intravenous delivery. Therefore, the intramuscular administration of rAAV-HK may be used in gene therapy for hypertension.
Similar content being viewed by others
Article PDF
References
Kitamura NKH, Fukushima D, Takagaki Y, Miyata T, Nakaniski S . Structural organization of the human kininogen gene and a model for its evolution. J Biol Chem 1985; 260: 8610–7.
Müller-Esterl W IS, Nakaniski S . Kininogens revisited. Trends Biochem Sci 1986; 11: 336–9.
Nakaniski SSP . Precursor and kininogen: their structures, gene organizations, and regulation. Physiol Rev 1987; 67: 1117–42.
Adam AAA, Caloy G, Closset J, Damas J, Franchiment P . Human kininogens of low and high molecular mass: quantification by radioimmunoassay and determination of reference values. Clin Chem 1985; 31: 423–6.
harma JNUK, Noor AR, Rahman AR . Blood pressure regulation by the kallikrein-kinin system. Gen Pharmacol 1996; 27: 55–63.
Katori MMM . Pivotal role of renal kallikrein-kininsystem in the development of hypertension and approaches to new drugs based on this relationship. Jpn Pharmacol 1996; 70: 95–128.
Margolius HS . Kallikreins and kinins: some unanswered questions about system characteristics and roles in human disease. Hypertension 1995; 26: 221–9.
Xiong WCJ, Chao L . Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension 1995; 25 ( 4 Pt 2): 715–9.
Murakami HYK, Chao L, Chao J . Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int 1998; 53: 1305–13.
Chao JZJ, Lin KF, Chao L . Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy and renal injury in Dahl salt-sensitive rats. Hum Gene Ther 1998; 9: 21–31.
Chao JZJ, Lin KF, Chao L . Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int 1998; 54: 1250–60.
Dobrzynski EYH, Chao J, Chao L . Adenovirus- mediated kal-likrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunopharma-cology 1999; 44: 57–65.
Wang TL, Zhao C, Chen C, Li J, Chao J, Chao L, et al. Recom-binant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Therapy 2004; 11: 1342–50.
Xiao X, Li J, Samulski RJ . Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224–32.
Auricchio A, Hildinger M, O'Connor E, Gao G, Wilson JM . Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Human Gene Therapy 2001; 12: 71–6.
Gao GP, Qu G, Faust LZ, Engdahl RK, Xiao W, Hughes JV, et al. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther 1998; 9: 2353–62.
Dobrzynski EMD, Agata J, Zhu J, Chao J, Chao L . Adrenomedullin improves cardiac function and prevents renal damage in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2002; 283: E1291–E1298.
MacColl GS, Goldspink G, Bouloux PM . Using skeletal muscle as an artificial endocrine tissue. J Endocrinol 1999; 162: 1–9.
Danko I, Fritz, JD, Jiao S, Hogan K, Latendresse JS, Wolff JA . Pharmacological enhancement of in vivo foreign gene expression in muscle. Gene Therapy 1994; 1: 114–21.
Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292: 2343–9.
Monahan PE SR . AAV vectors: is clinical success on the horizon? Gene Ther 2000; 7 ( 1): 24–30.
Liu F LK, Huang L . Systemic administration of naked DNA: gene transfer to skeletal muscle. Mol Interv 2001; 1: 168–72.
Blau HM, Springer ML . Muscle-mediated gene therapy. N Engl J Med 1995; 333: 1554–6.
Wang B, Li J, Xiao X . From the cover: adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 2000; 97: 13714–9.
Bohl D, Bosch A, Cardona A, Salvetti A, Heard JM . Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle. Blood 2000; 95: 2793–8.
Schmaier AH . The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am J Physiol Regul Integr Comp Physiol 2003; 285: R1–R13.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was supported by grants from National Natural Science Foundation Committee (No 30470824), National 863 project (No 2001AA217121 and 2004AA-217060), 973 project (No G2000056901), Wuhan City International Collaboration project (No 997005135G), and the National Education Ministration project (No 20040487079).
Rights and permissions
About this article
Cite this article
Wang, T., Hou, Lb., Liu, Zj. et al. Intramuscular delivery of rAAV-mediated kallikrein gene reduces hypertension and prevents cardiovascular injuries in model rats. Acta Pharmacol Sin 28, 1898–1906 (2007). https://doi.org/10.1111/j.1745-7254.2007.00677.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00677.x
Keywords
This article is cited by
-
Decorin Induces Cardiac Hypertrophy by Regulating the CaMKII/MEF-2 Signaling Pathway In Vivo
Current Medical Science (2021)
-
Recombinant adeno-associated virus-mediated human kallikrein gene therapy protects against hypertensive target organ injuries through inhibiting cell apoptosis
Acta Pharmacologica Sinica (2009)